12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Enbrel etanercept recombinant p75 TNF receptor regulatory update

Canada granted marketing approval for Enbrel as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >